Clinical trial · Interventional
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for all groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Elotuzumab | Biological | Elotuzumab | ALIAS |
| Nivolumab | Biological | Nivolumab | ALIAS |
| Pomalidomide | Drug | Pomalidomide | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Investigational Arm
- description
- Nivolumab, Pomalidomide and Dexamethasone Enrollment is closed for this arm
- interventionNames
- Biological: Nivolumab
- Drug: Pomalidomide
- Drug: Dexamethasone
- type
- ACTIVE_COMPARATOR
- label
- Control Arm
- description
- Pomalidomide and Dexamethasone Enrollment is closed for this arm
- interventionNames
- Drug: Pomalidomide
- Drug: Dexamethasone
- type
- EXPERIMENTAL
- label
- Exploratory Arm
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Refractory or relapsed and refractory multiple myeloma * Measurable disease * Have received ≥ 2 lines of prior therapy which must have included an immune modulatory drug (IMiD) and a proteasome inhibitor alone or in combination Exclusion Criteria: * Solitary bone or extramedullary plasmacytoma disease only * Active plasma cell leukemia Other protocol defined inclusion/exclusion criteria apply
References
Publications (0)
Data not yet available